EverPoint Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

EverPoint Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$53.8M	Buy	+730,000	New	+$59.4M	1%	15
2016 Q1	–	Sell	-20,000	Closed	-$2.52M	–	546
2015 Q4	$2.52M	Buy	+20,000	New	+$2.41M	0.05%	360
2015 Q2	–	Sell	-80,000	Closed	-$9.44M	–	595
2015 Q1	$9.44M	Sell	80,000 -75,000	-48%	-$8.99M	0.18%	180
2014 Q4	$18.4M	Sell	155,000 -25,000	-14%	-$2.82M	0.41%	78
2014 Q3	$20.2M	Buy	+180,000	New	+$17.1M	0.46%	53

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EverPoint Asset Management's VRTX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2016: 730,000 shares worth $53.8M. The stake represents 1% of the portfolio and ranks #15 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in VRTX as recently as Q4 2015.

EverPoint Asset Management first reported a position in VRTX in Q3 2014 and has held it in 5 quarters since. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

EverPoint Asset Management held 730,000 shares of Vertex Pharmaceuticals worth $53.8M as of Q4 2016.
Vertex Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
Vertex Pharmaceuticals made up 1% of EverPoint Asset Management's portfolio in Q4 2016, its #15 holding.
EverPoint Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 5 quarters since.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.